Interval Cancers in a Population-Based Screening Program for Colorectal Cancer in Catalonia, Spain
Table 3
Program sensitivity according to demographic, screening, and tumor characteristics.
Screen-detected CRC
Interval CRC ≤30 months‡
CRC diagnosed >30 months‡
Program sensitivity*
(%)
(%)
(%)
%
Gender
Men
65 (67.0)
47 (63.5)
62 (63.9)
58.0
Women
32 (33.0)
27 (36.5)
35 (36.1)
54.0
Age at diagnosis
50–59
29 (33.3)
13 (17.6)
5 (5.2)
69.0
60–69
45 (51.7)
54 (73.0)
32 (33.0)
45.5
≥70
23 (14.9)
7 (9.5)
60 (61.9)
76.7
Screening
First screening
53 (54.6)
26 (35.1)
58 (59.8)
67.1
Successive screenings
44 (45.4)
48 (64.9)
39 (40.2)
47.8
Last screening round
1
23 (23.7)
11 (14.9)
38 (39.2)
67.6
2
13 (13.4)
14 (18.9)
34 (35.1)
48.1
3
27 (27.8)
20 (27.0)
14 (14.4)
57.4
4
34 (35.1)
29 (39.2)†
11 (11.3)#
54.0
Number of screens
1
53 (54.6)
26 (35.1)
58 (59.8)
67.1
2
17 (17.5)
27 (36.5)
30 (30.9)
38.6
3
19 (19.6)
16 (21.6)
7 (7.2)
54.3
4
8 (8.2)
5 (6.8)
2 (2.1)
61.5
Tumor site**
Proximal
23 (23.7)
15 (25.0)
28 (40.0)
60.5
Distal
56 (57.7)
20 (33.3)
24 (34.3)
73.7
Rectum
18 (18.6)
25 (41.7)
18 (25.7)
41.9
Tumor stage**
I
39 (40.2)
9 (14.8)
14 (17.3)
81.3
II
18 (18.6)
17 (27.9)
27 (33.3)
51.4
III
30 (30.9)
28 (45.9)
27 (33.3)
51.7
IV
10 (10.3)
7 (11.5)
13 (16.0)
58.8
Only CRC detected in individuals with a negative result in their last screening were considered; *sensitivity expressed as the proportion of CRC diagnosed during the screening divided by all CRC diagnosed among screening participants up to 30 months; **variables with missing values; †26 CRC diagnosed after a negative gFOBT and 3 CRC diagnosed after a negative FIT; 9 CRC diagnosed after a negative gFOBT and 2 CRC diagnosed after a negative FIT.
